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Abstract: On a yearly basis there are 3–5 million severe cases and 250,000–500,000 deaths 
worldwide attributed to inﬂ  uenza. Four antiviral medications are currently available on the 
market; however, resistance has resulted in the armamentarium being shrunk to two remaining 
active treatment options for inﬂ  uenza. These two neuraminidase inhibitors, oseltamivir and 
zanamivir, are recommended for the treatment and prophylaxis of inﬂ  uenza A and B in 
children and adults. Zanamivir, which is the focus of this review, is an inhaled antiviral that has 
shown beneﬁ  t in the community, household, and nursing home population for post-exposure 
prophylaxis. Zanamivir protection rates range from 67%–84% in clinical trials of adults and 
children. Although the inﬂ  uenza vaccine remains the best modality to combat the disease, 
zanamivir may also assist in decreasing morbidity associated with inﬂ  uenza A and B. 
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Inﬂ  uenza is responsible for 3–5 million severe cases and 250,000–500,000 deaths 
worldwide annually (WHO 2003). Inﬂ  uenza produces a seasonal epidemic in both 
developed and developing countries. Death and hospitalizations mainly occur in the 
high-risk populations such as the elderly and those with chronic illnesses. Humans are 
affected by inﬂ  uenza type A and B resulting in an upper respiratory tract infection. 
Vaccination against the inﬂ  uenza virus serves as the best prevention when combat-
ing the virus. However, the vaccine does not protect all due to the antigenic shift of 
the virus strains as it travels the world. Though antiviral medications do not replace 
the vaccine, they are utilized for prophylaxis and relief of symptoms associated with 
inﬂ  uenza. 
Two classes of antiviral agents have demonstrated efﬁ  cacy against the inﬂ  uenza 
virus: M2 ion channel inhibitors (adamantanes derivatives: amantadine and rimanta-
dine) and neuraminidase inhibitors (oseltamivir and zanamivir). The adamantanes have 
efﬁ  cacy against inﬂ  uenza type A, where as the neuraminidase inhibitors are effective 
for both type A and B. All antiviral agents can be used for prophylaxis or treatment 
of inﬂ  uenza. Yet, over the past three years the inﬂ  uenza virus has shown increased 
resistance to the adamantanes worldwide with an associated increase from 1.9% to 
12.3% (CDC 2006). Due to this growth in resistance and speciﬁ  c isolates identiﬁ  ed in 
2005–2006, the treatment and prophylaxis with these therapeutic agents are no longer 
recommended in the US. Therefore, the neuraminidase inhibitors may see increased 
use worldwide during subsequent ﬂ  u seasons.
This review will focus on zanamivir, a neuraminidase inhibitor, for the prophylaxis 
of inﬂ  uenza in children and adults. Zanamivir is a micronized, dry powder inhaled 
antiviral agent that inhibits the neuraminidase molecule active site on the surface of 
the inﬂ  uenza virus. This is thought to prevent infection and distribution of the virus Therapeutics and Clinical Risk Management 2007:3(3) 462
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to uninfected cells. Zanamivir is indicated for prophylaxis of 
inﬂ  uenza type A and B in children 5 years of age and older. 
It is only commercially available in an inhaled form due to 
poor oral bioavailability and should be used with a diskhaler® 
(Glaxo Wellcome UK Ltd, Middlesex, UK) device, which is 
provided with the medication. The medication is provided in 
foil blister packs (rotadisks) which are inserted individually 
and replaced in the diskhaler®. Each rotadisk contains 4 doses 
and provides 5 mg per dose. Five rotadisks are packaged 
with the diskhaler®. The prophylaxis dose for all ages of 
zanamivir is 10 mg (two 5 mg blisters) inhaled once daily, 
at the same time each day, for 10 days of therapy. Zanamivir 
should be initiated within 1.5 days of symptom onset for the 
index case in a household setting. For a community outbreak, 
zanamivir should be initiated within 5 days of identiﬁ  cation 
and be administered for a total of 28 days of therapy. Data 
is not available regarding the use of zanamivir if the recom-
mended initiation time frame has past. 
Intranasal zanamivir has been evaluated but provided no 
greater efﬁ  cacy than placebo or when added to the inhaled 
formulation; thus, intranasal administration is not currently 
recommended and a dosage formulation is not available 
(Kaiser et al 2000). An IV formulation of zanamivir was 
studied in one trial (Calfee et al 1999); however, this dosage 
form is not marketed. 
Zanamivir has low protein binding and is excreted primar-
ily unchanged in the urine. No adjustment is needed for renal 
dysfunction as zanamivir has limited systemic absorption. 
Zanamivir appears to be well tolerated as adverse effects are 
reported as being similar to placebo and difﬁ  cult to distin-
guish from the inﬂ  uenza virus. The most common adverse 
effects seen are headache, throat, and tonsil pain, and cough 
and nasal symptoms. Zanamivir lacks drug interactions and 
does not affect cytochrome P450 enzymes. Administering 
the live intranasal ﬂ  u vaccine concurrently with zanamivir 
may inhibit the vaccine replication. It is recommended to 
administer the vaccine at least 24 hours after zanamivir ces-
sation and to not provide zanamivir until 2 weeks following 
the vaccine. Caution should be utilized in patients with 
milk allergy considering that each blister contains 20 mg of 
lactose or milk protein. Zanamivir has not been studied in 
pregnancy and should only be used if the beneﬁ  t outweighs 
the risk to the fetus and mother. However, its low systemic 
absorption may be a possible beneﬁ  t for use considering this 
pharmacodynamic parameter. 
In addition, patients with chronic airway disease such as 
asthma or chronic obstructive pulmonary disease (COPD) 
should avoid zanamivir due to bronchospasm concerns. 
Although previous data found pulmonary function not 
signiﬁ  cantly affected by zanamivir (Cass et al 2000), post 
marketing reports led to the warning. If a patient routinely 
takes bronchodilators, it is recommended that the patient 
administer the bronchodilator prior to the zanamivir dose. 
However, if bronchospasms or a decline in respiratory func-
tion occurs after utilization, it is recommended to discontinue 
the product and seek treatment if warranted. 
Concerns exist regarding the patient administration 
technique and use of the inhaler. Although the diskhaler® 
does not require coordination with releasing the dose and in-
spiration, the device may be difﬁ  cult to use for some patient 
populations. In the pediatric population, it is challenging 
to have a young child inhale appropriately and obtain the 
desired quantity of drug. A parent may place zanamivir into 
the end of a straw prior to blowing through the straw forc-
ing the medication into the child’s throat which has been 
shown to be efﬁ  cacious (Imuta et al 2003). Thirty-eight 
elderly patients were assessed on their use of the device 
(Diggory et al 2001). After a 15 minute education period, 
these patients demonstrated use of the device. Patients 
could receive up to ﬁ  ve additional minutes of education 
after the initial period. Ten patients achieved perfect scores 
regarding the demonstration. After 24 hours, the patients 
were again asked to show how to use the device. Only ﬁ  ve 
patients had perfect scores and in general most patients 
scores decreased, p < 0.001. In this study, the elderly had 
trouble primarily with loading the disk in the device and 
priming the device. The straw technique may be useful in 
the elderly population as well. 
Prophylaxis studies
Zanamivir has several studies evaluating its use as a pro-
phylactic agent for inﬂ  uenza in children and adults. The ﬁ  rst 
double-blind trial randomized 1107 adults (18–64 years) to 
zanamivir (10 mg daily) or placebo for 4 weeks at the start 
of the 1997 inﬂ  uenza season (Monto et al 1999). The most 
prominent virus of 2006 was A/Sydney/5/97 (H3N2) which 
was not in the annual vaccine. The primary outcome was 
the number of individuals who had symptomatic, labora-
tory-conﬁ  rmed inﬂ  uenza. This was deﬁ  ned as a rise in titers 
and/or isolation of the inﬂ  uenza virus, and two or more of the 
following on three concurrent diary cards: cough, headache, 
sore throat, myalgia, feverishness, or temperature 37.8 ºC. 
Patients recorded symptoms and temperatures twice daily 
on the diary cards that were checked weekly and were asked Therapeutics and Clinical Risk Management 2007:3(3) 463
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to contact the study center if any respiratory symptoms 
developed. Only 14% of patients in the study received 
the inﬂ  uenza vaccine. Symptomatic, laboratory-conﬁ  rmed 
clinical inﬂ  uenza occurred in 2% and 6.1% of the zanamivir 
group versus placebo, respectively. Zanamivir provided a 
67% efﬁ  cacy in prevention laboratory-conﬁ  rmed clinical 
inﬂ  uenza versus placebo, p < 0.001. It also provided 84% 
efﬁ  cacy against laboratory-conﬁ  rmed inﬂ  uenza with fever, 
p = 0.001. Zanamivir was 43% efﬁ  cacious against all febrile 
illnesses, p = 0.009 and 31% efﬁ  cacious against inﬂ  uenza 
infection, with or without symptoms, p = 0.03. In the subset 
of unvaccinated patients, zanamivir decreased symptomatic, 
laboratory-conﬁ  rmed inﬂ  uenza by 60% (p = 0.009) and 
conﬁ  rmed inﬂ  uenza with fever by 81% (p = 0.004). Overall, 
no difference in adverse effects was found between groups 
and compliance was high in both groups. A severe adverse 
effect was found in 1 patient in each group. Four patients in 
the zanamivir group and seven patients in the placebo group 
discontinued the medication due to drug-related events, 
speciﬁ  cs were not stated. 
Another study evaluated zanamivir for a community 
outbreak in high-risk patients 12 years of age or older. (Data 
on File, Relenza 2000) This multi-center, double-blind study 
randomized patients from various countries to zanamivir 10 mg 
daily or placebo for 28 days during December 2000–April 
2001. Therapy was initiated within 5 days of identifying the 
community outbreak. There were 1678 patients randomized 
to the zanamivir group and 1685 patients in the placebo 
group. Patient ages ranged from 12–94 years of age, mean 
60 years. Fifty-six percent of the patients were over 65 years 
of age. Sixty-seven percent and 68% of the zanamivir and 
placebo group, respectively, had received the ﬂ  u vaccine for 
the season. This intention-to-treat analysis determined only 4 
patients (0.2%) in the zanamivir group developed symptomatic 
inﬂ  uenza with conﬁ  rmed serology/culture versus 23 patients 
(1.4%) in the placebo group, p < 0.001. Symptomatic inﬂ  uenza 
was deﬁ  ned as two of the following symptoms reported for 
3 consecutive days on diary cards: feverish or temperature 
37.8 ºC, headache, cough, sore throat, or muscle/joint 
aches and pains. Only 4 patients in the zanamivir group 
and 21 patients in the placebo group were diagnosed with 
symptomatic inﬂ  uenza with culture/serology positive results 
on Day 2–28 (95% conﬁ  dence interval [CI] 0.07, 0.49). This 
was similar for Day 3–28 as well (95% CI 0.07, 0.52). Adverse 
effects were similar between both groups. Five percent of 
patients in each group withdrew from the study for similar 
reasons, speciﬁ  cs were not provided in the study. 
Kaiser and colleagues (2000) randomized 575 patients 
(age 13–65 years) to inhaled zanamivir, intranasal zanami-
vir, inhaled and intranasal zanamivir, or placebo after close 
contact with people who had inﬂ  uenza-like illnesses for 
no longer than 4 days. Close contact was deﬁ  ned as living 
in the same home, sleeping in the same room, or conﬁ  ned 
in the same room for extended periods of time. This was a 
multicenter trial conducted during the 1995–1996 inﬂ  uenza 
season. Unstable chronic illness, inﬂ  uenza vaccination, or 
anti-inﬂ  uenza medications during the previous days were trial 
exclusions. Treatment medication or placebo was adminis-
tered for 5 days. No signiﬁ  cant difference was found between 
the four groups for patients developing proven inﬂ  uenza after 
exposure; however, the trial did not reach its power as 840 
patients were not enrolled. The inhaled zanamivir appeared 
to prevent more infections than the intranasal zanamivir 
or placebo; however, this was not statistically signiﬁ  cant. 
Intranasal zanamivir produced results similar to those of 
the placebo group. The authors determined that intranasal 
route was not effective and acknowledged that ﬁ  ve days of 
prophylactic therapy may not be sufﬁ  cient, thus studies of 
longer duration are warranted. 
The Zanamivir Family Study Group conducted a mul-
ticenter, double-blind, parallel, placebo controlled study of 
zanamivir for prophylaxis in a family setting from December 
1998 to April 1999 (Hayden et al 2000). Families with 2–5 
people, one being an adult and at least one a child, age 5–17 
years, were enrolled once one person developed inﬂ  uenza-
like illness. All eligible family members began taking 
zanamivir or placebo within 36 hours of symptom onset in 
the index case. Patients who were immunocompromised, 
pregnant, breast feeding, were taking an antiviral medication, 
or less than 5 years of age were excluded from the study. 
The index case was administered the treatment regimen of 
zanamivir or placebo. Three hundred thirty-seven families 
(1158 participants) were randomized to treatment or pla-
cebo. Both inﬂ  uenza A and B were conﬁ  rmed in the study. 
The primary end point was the proportion of families who 
had one or more family members (household contacts) that 
developed symptomatic, laboratory-conﬁ  rmed inﬂ  uenza. 
Symptomatic was deﬁ  ned as possessing at least two of 
the following: temperature 37.8 ºC, feverishness, cough, 
headache, sore throat, or myalgia on three consecutive diary 
card entries. This occurred in 4.1% of families in the zana-
mivir group versus 19% of families in the placebo group, 
p < 0.001. Families with laboratory-conﬁ  rmed inﬂ  uenza in 
the index case experienced a proportionally higher incidence Therapeutics and Clinical Risk Management 2007:3(3) 464
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of inﬂ  uenza, 8% for the zanamivir group versus 29% in the 
placebo group, p < 0.001. Overall, zanamivir provided a 79% 
protection rate from inﬂ  uenza among families. Based on 
examining symptom onset ≥1 day after prophylaxis initiation, 
zanamivir’s protection rate increased to 84%, p < 0.001. No 
development of resistance to zanamivir was seen in the study 
via viral sequencing. Three patients discontinued zanamivir 
due to adverse effects. One stopped the medication due 
to gastrointestinal pain and discomfort and the other two 
patients stopped due to headaches. Of those patients with 
asthma requiring medication, 11% of the placebo group had 
an exacerbation versus 6% in the zanamivir group. 
In the previous study, protection could occur from 
treating the index case, thus decreasing viral shedding; 
therefore, Monto and colleagues (2002) evaluated zanamivir 
prophylaxis in 487 families in which the index case was not 
treated. This multicenter, double-blind, parallel, placebo-
controlled trial randomized families (1291 contacts) to 
zanamivir or placebo for 10 days. Index patients were 
only tested for the inﬂ  uenza virus, but not treated. Family 
inclusions were the same as the above study and subjects 
had to start therapy within 36 hours of symptom onset in 
the index patient. One hundred and thirty-two contacts had 
been vaccinated for inﬂ  uenza. The zanamivir and placebo 
group were similar regarding vaccination. The primary 
end point was laboratory–conﬁ  rmed inﬂ  uenza in families 
during the period of prophylaxis, day 1–11. This study was 
conducted from June 2000–April 2001 and both inﬂ  uenza 
type A and B were documented. Zanamivir reduced the 
occurrence of symptomatic, laboratory-conﬁ  rmed inﬂ  uenza 
by 81% in households, p < 0.001. A similar reduction 
was also seen when evaluating individual contacts versus 
families. No evidence of resistance was found in clinical 
isolates. Inﬂ  uenza-like illness was the common adverse 
effect seen in the study, yet zanamivir was well tolerated in 
all. Fifty-eight patients were classiﬁ  ed to have an underlying 
respiratory condition, mostly asthma. Two of these patients 
had bronchospasms and both were in the placebo group. 
Three studies have speciﬁ  cally evaluated zanamivir efﬁ  -
cacy in the nursing home population for prophylaxis. The ﬁ  rst 
pilot study randomized patients to zanamivir 10 mg inhaled 
and 4.4 mg intranasal twice daily or rimantadine 100 mg once 
daily for 14 days for inﬂ  uenza A outbreaks (Schilling et al 
1998). For inﬂ  uenza B outbreaks, patients received zanami-
vir as stated or no medication. Study nurses administered 
the medications for the pilot. Sixty-ﬁ  ve patients received 
zanamivir and 23 received rimantadine for an inﬂ  uenza A 
outbreak. No patients in the zanamivir group developed 
laboratory-conﬁ  rmed inﬂ  uenza A; although, one patient in 
the rimantadine group was positive. Eight patients versus one 
in the zanamivir group developed a respiratory illness versus 
placebo, respectively. Thirty-ﬁ  ve patients received zanamivir 
versus 17 who received nothing for an inﬂ  uenza B outbreak. 
Again, no patients had laboratory-conﬁ  rmed inﬂ  uenza B in 
the zanamivir group. One patient who did not receive the 
medication was inﬂ  uenza B positive. Only one patient in 
the zanamivir group had a respiratory illness, versus three 
who did not receive zanamivir. No serious adverse effects 
were reported with zanamivir. Most patients complained of 
nasal symptoms (16%), gastrointestinal symptoms (8%), and 
throat irritation (7%). Forty patients with mild to moderate 
COPD did not have a difference in severity or incidence of 
adverse effects. 
A larger multicenter, double-blind trial randomized 489 
asymptomatic nursing home patients to zanamivir (10 mg 
inhaled daily) or placebo for 14 days after an inﬂ  uenza outbreak 
was recognized (Ambrozaitis et al 2005). The study occurred 
over three inﬂ  uenza seasons, thus a few patients (n = 5) were 
randomized twice. Twice weekly evaluation for respiratory 
illness was conducted. Only 9% of patients were vaccinated. 
Approximately 85% of patients were considered high-risk 
(age 65 years, diabetes, respiratory, or cardiac condition). 
Symptomatic, laboratory-conﬁ  rmed inﬂ  uenza occurred in 6% 
and 9% of the zanamivir and placebo patients, respectively, 
p = 0.355. All cases occurred in a site where no one had the 
vaccination and more than half of the failures occurred within 
2 days of the outbreak. Collectively, zanamivir provided 
a 32% protection versus placebo. Laboratory-conﬁ  rmed 
influenza with fever occurred in 2% of the zanamivir 
and 6% of the placebo group, p = 0.043. This equates to 
zanamivir providing 70% protection against febrile inﬂ  uenza. 
Complications of the inﬂ  uenza illness and adverse effects of 
zanamivir were not signiﬁ  cantly different between groups. 
No evidence of zanamivir resistance was found in isolates. 
A similar study was conducted in the US at multiple 
sites over the same three year period (Gravenstein et al 
2005). There were 375 patients were randomized to inhaled 
zanamivir (10 mg daily) or placebo for 14 days. For inﬂ  u-
enza A outbreaks, rimantadine (100 mg daily) or placebo 
tablets was also administered. Overall, 482 randomizations 
occurred as some patients were randomized twice or three 
times (zanamivir: 238, rimantadine: 231, placebo: 13). 
Almost all patients were vaccinated for the current inﬂ  uenza 
season and 96% of patients were considered high-risk (as Therapeutics and Clinical Risk Management 2007:3(3) 465
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stated previously). Symptoms were assessed in each patient 
throughout the study. Only 3% of patients in the zanamivir 
group versus 8% of the rimantadine group developed symp-
tomatic, laboratory-conﬁ  rmed inﬂ  uenza A, p = 0.038. This 
results in 61% additional protection using zanamivir versus 
rimantadine. Almost half of the failures occurred within the 
ﬁ  rst two days. When evaluating days 2–15, 2% versus 7% of 
patients developed symptomatic, laboratory positive inﬂ  u-
enza with zanamivir or rimantadine, respectively, p = 0.024. 
Zanamivir showed an additional 68% efﬁ  cacy over riman-
tadine. When examining days 3–15, zanamivir provided an 
additional 77% efﬁ  cacy. Only 1% of zanamivir versus 6% 
of rimantadine patients developed symptomatic, laboratory 
conﬁ  rmed inﬂ  uenza, p = 0.02. No signiﬁ  cant differences 
were seen between the groups in regards to adverse effects. 
Complications occurred in 3% of patients on rimantadine 
versus 1% of patients on zanamivir, p = 0.109. No resistance 
was identiﬁ  ed with zanamivir in the isolates; however, 38% 
were resistant to rimantadine. 
Intravenous formulation
An intravenous formulation of zanamivir was studied in 16 
healthy males who were inoculated with the virus (Calfee 
et al 1999). This double-blind study randomized patients to 
zanamivir 600 mg IV over 30 minutes twice daily for 5 days 
or placebo. The medication was provided 4 hours prior to an 
H1N1 virus exposure. Symptoms were assessed twice daily 
throughout the period. Serologic infection was identiﬁ  ed 
in one patient in the zanamivir group, p < 0.005; however, 
no viral shedding was found, p < 0.005. One patient in the 
zanamivir group versus seven in the placebo group had fever, 
p < 0.05. Prophylactic intravenous zanamivir was found to be 
well-tolerated and protected against the inﬂ  uenza A virus. 
Conclusion
Although the inﬂ  uenza vaccine remains the optimal inter-
vention for prevention, zanamivir has proven efﬁ  cacy and 
safety for post-exposure prophylaxis of inﬂ  uenza A and B 
viruses in adults and children. Zanamivir has been evaluated 
in the community, home, and nursing home setting. Caution 
should be used in patients with underlying airway diseases. 
Education on the appropriate use of the device is warranted 
in all patient populations. 
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